<DOC>
	<DOCNO>NCT01423851</DOCNO>
	<brief_summary>The purpose study determine safety tolerability orally administer NS-018 patient Primary Myelofibrosis ( PMF ) , Post-polycythemia Vera Myelofibrosis ( post-PV MF ) , Post-essential Thrombocythemia Myelofibrosis ( post-ET MF )</brief_summary>
	<brief_title>Safety Tolerability Study Oral NS-018 Patients With Primary Myelofibrosis ( MF ) , Post-polycythemia Vera MF Post-essential Thrombocythemia MF</brief_title>
	<detailed_description>This Phase 1/2 study currently enrol JAK2 failure Phase 2 portion study .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Primary myelofibrosis , postPV MF , postET MF require therapy MF patient must receive prior JAK2 inhibitor therapy , find intolerant , refractory/relapsed prior JAK2 inhibitor therapy , base investigator assessment ≥18 year old ECOG Performance Status ≤ 3 Estimated life expectancy ≥12 week Male nonpregnant , nonlactating female patient Serum creatinine ≤1.5 × upper limit normal ( ULN ) OR estimate creatinine clearance ( CrCl ) ≥ 40 ml/min/1.73 m2 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤3 × upper limit normal ( ULN ) total bilirubin ≤1.5 × ULN . If total bilirubin elevate 1.5 x 3 x ULN , patient direct bilirubin ≤ 1.5 X ULN eligible Phase II portion . Absolute neutrophil count ( ANC ) &gt; 1000/μL Platelet count &gt; 25,000/μL QTcB ≤ 480 msec No MFdirected treatment least 2 week prior initiation NS018 , include use corticosteroid Myelofibrosis symptom blood count management . Low dose corticosteroid ≤ 10 mg/day prednisone equivalent allow nonmyelofibrosis purpose . Active , uncontrolled systemic infection Patients unresolved toxicity great Grade 1 previous anticancer therapy Potentially curative therapy available Currently take medication substantially metabolize cytochrome P450 ( CYP ) 1A2 CYP3A4 take medication know strong inhibitor inducer CYP3A4 Patients serious cardiac condition within past 6 month Pregnant lactate Radiation therapy splenomegaly within 6 month prior study entry Splenectomy ( Phase 2 portion study ) Known HIV positive status Known active hepatitis , history viral hepatitis B hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Keywords provide NS Pharma , Inc. :</keyword>
	<keyword>JAK2 kinase inhibitor</keyword>
	<keyword>NS-018</keyword>
	<keyword>Myeloproliferative Neoplasms</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>post-Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Thrombocythemia , Essential</keyword>
	<keyword>PMF</keyword>
	<keyword>post-PV MF</keyword>
	<keyword>post-ET MF</keyword>
</DOC>